5-Aminosalicylate (5-ASA)
https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Central Zone. Gastroenterology.
Halifax, NS:
Nova Scotia Health Authority
, 2016.
- Pamphlet Number
- 1483
- Available Online
- View Pamphlet
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Central Zone. Gastroenterology
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2016
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (6 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Crohn Disease - drug therapy
- Colitis - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Crohn's disease
- Colitis
- Abstract
- 5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
- Responsibility
- Prepared by: Jennifer Stewart, RN; Gastroenterology
- Prepared by: Kaleigh MacIsaac, B.ScPharm; Gastroenterology
- Revised by: Phyllis Durning, RN
- Revised by: Alison Harding, B.Sc.
- Pamphlet Number
- 1483
Adalimumab (Humira) therapy
https://libcat.nshealth.ca/en/permalink/chpams35127
Nova Scotia Health Authority. Central Zone. Gastroenterology.
Halifax, NS:
Nova Scotia Health Authority
, 2016.
- Pamphlet Number
- 1207
- Available Online
- View Pamphlet
Your healthcare provider feels that treatment with adalimumab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Central Zone. Gastroenterology
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2016
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Adalimumab
- Inflammatory Bowel Diseases - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Specialty
- Medications
- Abstract
- Your healthcare provider feels that treatment with adalimumab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Responsibility
- Prepared by: Division of Gastroenterology
- Pamphlet Number
- 1207
Corticosteroid therapy in inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35480
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1546
- Available Online
- View Pamphlet
Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Alternate Title
- Corticosteroid therapy in IBD
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Prednisone
- Subjects (LCSH)
- Inflammatory bowel diseases
- Prednisone
- Specialty
- Gastrointestinal System
- Medications
- Abstract
- Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Notes
- This pamphlet replaced pamphlet 1139, Prednisone Therapy.
- Responsibility
- Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Pamphlet Number
- 1546
Golimumab (Simponi) therapy
https://libcat.nshealth.ca/en/permalink/chpams35651
Nova Scotia Health Authority. Central Zone. Division of Gastroenterology.
Halifax, NS:
Nova Scotia Health Authority
, 2016.
- Pamphlet Number
- 1641
- Available Online
- View Pamphlet
Your healthcare provider feels that treatment with golimumab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Available Online
- View Pamphlet
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2016
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Golimumab
- Inflammatory Bowel Diseases - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Specialty
- Medications
- Abstract
- Your healthcare provider feels that treatment with golimumab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Responsibility
- Prepared by: Division of Gastroenterology
- Pamphlet Number
- 1641
Infliximab (Remicade) therapy
https://libcat.nshealth.ca/en/permalink/chpams34944
Nova Scotia Health Authority. Central Zone. Gastroenterology.
Halifax, NS:
Nova Scotia Health Authority
, 2016.
- Pamphlet Number
- 1140
- Available Online
- View Pamphlet
Your healthcare provider feels that treatment with infliximab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Central Zone. Gastroenterology
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2016
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Infliximab
- Subjects (LCSH)
- Inflammatory bowel diseases
- Infliximab
- Abstract
- Your healthcare provider feels that treatment with infliximab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Responsibility
- Prepared by: Division of Gastroenterology
- Pamphlet Number
- 1140
Treatment of Inflammatory Bowel Disease with Biologics
https://libcat.nshealth.ca/en/permalink/provcat42935
edited by Adam S. Cheifetz, Joseph D. Feuerstein.
--Cham, Switzerland:
Springer
, c2018.
- Available Online
- View e-Book
- Location
- Online
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment …
- Available Online
- View e-Book
- Other Authors
- Cheifetz, Adam S.
- Feuerstein, Joseph D.
- Responsibility
- edited by Adam S. Cheifetz, Joseph D. Feuerstein
- Place of Publication
- Cham, Switzerland
- Publisher
- Springer
- Date of Publication
- c2018
- Physical Description
- 1 online resource (xi, 335 p.) : 22 illus., 19 illus. in color
- ISBN
- 9783319602769
- 9783319602752 (print ed.)
- 9783319602776 (print ed.)
- 9783319868233 (print ed.)
- Subjects (MeSH)
- Anti-Inflammatory Agents - therapeutic use
- Biological Products - therapeutic use
- Inflammatory Bowel Diseases - drug therapy
- Specialty
- Biological Therapy
- Gastroenterology
- Abstract
- This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.
- Contents
- Mechanism of Action and Pharmacokinetics of Biologics -- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis -- Anti-tumor Necrosis Factor Agents in Crohn's Disease -- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease -- Use of Biologics in the Postoperative Management of Crohn's Disease -- Biologics in Pregnancy and Breastfeeding -- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease -- Therapeutic Drug Monitoring of Biologic Agents -- Use of Biologics in Crohn's Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks -- Cessation of Biologics—Can it be Done? -- Biologic Therapy in Pediatric Inflammatory Bowel Disease -- Infectious Complications of Biologics -- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy -- Non-infectious and Non-malignant Complications of Biologics -- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances -- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications -- Novel Agents in Inflammatory Bowel Disease -- Quality, Safety, and Practical Considerations of Using Biologic Therapies.
- Format
- e-Book
- Location
- Online
